Cambridge, MA, United States
Cambridge, MA, United States

Time filter

Source Type

Patent
Momenta Pharmaceuticals Inc. | Date: 2016-04-28

The present invention relates to compositions and methods of engineered IgG Fc constructs, wherein said Fc constructs include one or more Fc domains.


Patent
Momenta Pharmaceuticals Inc. | Date: 2016-09-01

The present invention relates to the characterization and production of biologics.


Patent
Momenta Pharmaceuticals Inc. | Date: 2017-03-08

The present invention relates to the determination of levels or expression of particular biomarkers in biological samples which can be utilized to diagnose, prognose, and treat Kawasaki disease in subjects, and further to select subjects who would benefit from a Kawasaki disease therapy other than, or in addition to, IVIG treatment. Accordingly, the present invention encompasses methods and compositions that utilize these biomarkers for the diagnosis, prognosis, and treatment of Kawasaki disease.


Patent
Momenta Pharmaceuticals Inc. | Date: 2017-03-08

The present invention relates to compositions and methods of engineered IgG Fc constructs, wherein said Fc constructs include one or more Fc domains.


Patent
Momenta Pharmaceuticals Inc. | Date: 2015-04-03

Methods of treating cancer comprising administering a LMWH.


Patent
Momenta Pharmaceuticals Inc. | Date: 2016-09-01

The present invention relates to the characterization and production of biosimilars.


Patent
Momenta Pharmaceuticals Inc. | Date: 2016-04-29

Methods of producing, processing, and manufacturing LMWHs.


Polysaccharide preparations lacking substantial anticoagulant activity are provided herein. Methods of making and using such preparations are provided.


Patent
Momenta Pharmaceuticals Inc. | Date: 2016-09-09

Polypeptides having target levels of C-terminal variants are described.


Patent
Momenta Pharmaceuticals Inc. | Date: 2016-08-19

A multi-dimensional chromatographic method for the separation of N-glycans. The method comprises providing a glycan preparation that includes at least one negatively charged N-glycan. The glycan preparation is then separated by anion-exchange chromatography and at least one secondary chromatographic technique.

Loading Momenta Pharmaceuticals Inc. collaborators
Loading Momenta Pharmaceuticals Inc. collaborators